Compare Freeport-McMoRan Inc (FCX) vs Sanofi SA (SNY) Price & Performance

Freeport-McMoRan IncTrade

Sanofi SATrade

Price performance (Past 24H)

Key statistics

Freeport-McMoRan Inc vs Sanofi SA — how do they compare? Freeport-McMoRan Inc trades at $69.21 (market cap $98.71B), while Sanofi SA trades at $43.25 (market cap $104.57B). The key difference: Freeport-McMoRan Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.

	FCX	SNY
Market Cap	$98.71B	$104.57B
Sector	Basic Materials	Health
52-Week High	$71.73	$52.34
52-Week Low	$35.34	$41.33
Enterprise Value	$104.99B	$124.48B
Dividend Yield	0.85%	5.56%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

FCX

Freeport-McMoRan poised for growth with strong copper market and solid financials, supporting a Buy rating.Seeking Alpha · 22 hours agoBullish Freeport's Q2 beats expectations with higher copper output and lower costs, but risks remain.Seeking Alpha · 22 hours agoBullish View details →

SNY

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish Global influenza vaccine market to grow to $13.32B by 2030, driven by aging population and vaccine innovationsResearchandmarkets.Com · 4 days agoNeutral View details →

About Freeport-McMoRan Inc

Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.